Sunday, 22 July 2018 - 15:33
  • it
  • de
  • en
  • fr


Xarelto significantly reduces major cardiovascular events

Results from the Phase III COMPASS study found that Xarelto (rivaroxaban) 2.5 mg twice daily, plus aspirin 100 mg once daily, significantly reduced the risk of major cardiovascular events: the rate of CV death, heart attack or stroke decreased by…

Xarelto superior to aspirin in preventing thrombosis

The prestigious New England Journal of Medicine published on Saturday a study which demonstrated that rivaroxaban is 70% more efficacious than aspirin in preventing blood clots from originating in blood vessels and does not entail the risk of internal bleeding…

FDA, no problems in ROCKET-AF trial for Xarelto

In July 2016, result accuracy problems were detected for the Alere INRatio device. This device was used to monitor warfarin therapy in the control group of the ROCKET-AF clinical trial, whose results supported the 2011 approval of Bayer’s Xarelto (rivaroxaban)….